Immunomedics (IMMU) Provides Durable Response Data for Sacituzumab Govitecan in Patients With Advanced Solid Cancers
Tweet Send to a Friend
Immunomedics, Inc., (Nasdaq: IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), produced durable responses that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
